Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.21.1
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Amortization expense $ 198,832 $ 198,832
Future amortization expense 790,000  
Future amortization expense, annual periods thereafter 788,000  
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]    
Purchase price 8,000,000  
Transaction cost 1,782  
Recognition of deferred tax liability 3,037,147  
Intangible asset, tax basis $ 1,782